Update 25 Feb 2021:

The purpose of this update is to provide the SF1409 Abstract of Bids to record the bids that were received on 22 February 2021.

********************************************************************************************************

Update 19 Feb 2021 (Additional Updates):

The purpose of this update is to provide Amendment 0003 to the Invitation for Bid and a copy of revised CDRL A001. The bid response date and time remains unchanged.

********************************************************************************************************

Update 19 Feb 2021:

The purpose of this update is to provide Q&A #2 for the final Invitation for Bid. 

********************************************************************************************************

Update 16 Feb 2021:

The purpose of this update is to provide Amendment 0002 to the final Invitation for Bid and extend the bid response date and time to 22 February 2021 at 12:00pm EST. 

********************************************************************************************************

Update 13 Feb 2021:

The purpose of this update is to: 

1. Provide Q&A #1 for the final Invitation for Bid.

2. Notify prospective bidders that the Government anticipates releasing Amendment 0002 on 16 February 2021. 

3.  Notify prospective bidders that the Government anticipates extending the bid response date to 22 February 2021. 

********************************************************************************************************

Update 10 Feb 2021:

The purpose of this update is to provide Amendment 0001 to the Invitation for Bid and a copy of CDRL A001. The bid response date and time remains unchanged. 

********************************************************************************************************

Update 09 Feb 2021:

The purpose of this update is to provide the final Invitation for Bid.  

********************************************************************************************************

Update 05 Feb 2021:

The purpose of this update is to provide answers to questions received on the presolicitation notice for the Synopsis: COVID Screening Testing of Asymptomatic Individuals, draft SOW and Section B that were posted on 29 January 2021. See the attached Synopsis_QA file. 

The due date for the "COVID-19 IFB Screening Feedback" responses remains unchanged at 04  February 2021. The Government does not intend to extend the due date for the feedback. The IFB is anticipated to be released mid-February. 

********************************************************************************************************

Update 29 Jan 2021:

Presolicitation Notice/Synopsis

INTRODUCTION:

THIS IS A PRE-SOLICITATION NOTICE ONLY

This notice does NOT constitute a request for proposal, request for quote, or invitation for bid. The intent of this pre-solicitation notice is for informational purposes only.

DESCRIPTION:

The Naval Air Systems Command has a requirement for onsite COVID-19 screening testing for asymptomatic employees. This notice is a follow-up to the Special Notice, “Request for Information (RFI): COVID Screening Testing of Asymptomatic Individuals” previously posted on the beta.Sam.gov website on 14 December 2020 to conduct market research and determine if there are sources capable of satisfying the requirement.

PROPOSED STRATEGY:

Based on the results of the market research, the Government anticipates that this requirement will be issued under an Invitation for Bid (IFB) as a commercial service using the procedures of FAR Part 12 Acquisition of Commercial Items, and FAR Part 14 Sealed Bidding. The Government intends to award a Firm fixed Price (FFP), single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract as a result of the IFB. The expected performance period is February 2021 through December 2021.

It is anticipated that this requirement will be solicited as a 100% small business set-aside under North American Industry Classification Standard (NAICS) code 541380 – Testing Laboratories with a size standard of $16.5M. 

DRAFT MILESTONES:

• Invitation for Bid (IFB) release is anticipated early February 2021
• Sealed Bids due mid-February 2021 - anticipate a 14 day response time (exact date will be established in the IFB)
• Contract award is anticipated late February 2021 with performance beginning immediately. 

QUESTIONS/COMMENTS:

Please provide your feedback and questions regarding this announcement and Draft Section B and Performance Work Statement documents to [email protected] and [email protected] no later than 1700 EST 04 February 2021. Please use the title “COVID Screening IFB Feedback” in the subject line when submitting your responses. Acknowledgment of receipt of questions will not be made. Responses to questions will be provided as updates to this announcement via this website. Telephone calls will not be accepted.

DISCLAIMER:

This announcement is for informational purposes only and does not commit the Government to award a contract as a result of this announcement. The Government is not seeking proposals at this time and will not accept unsolicited proposals.

Notifications of any updates or amendments to this synopsis will be posted on the https://sam.gov website only. Contractors are encouraged to register on the website. It is the sole responsibility of the potential offeror to continually review the website for changes.

These requirements are subject to change based on the Governments need. The final requirement will be defined under a formal IFB. Not responding to this announcement does not preclude participation in any future IFB, if issued. If an IFB is released, it will be posted on the https://sam.gov website along with any subsequent amendments. It is the responsibility of the potential offerors to monitor this website for additional information pertaining to this requirement.

Respondents are advised that the Government will not pay for any information or administrative costs incurred in response to this announcement. All costs associated with responding to this announcement will be solely at the expense of the interested party.

Update 05 Jan 2021:

The purpose of this update is to provide Q&A #4 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #4 file.

********************************************************************************************************

Update 31 Dec 2020:

The purpose of this update is to provide Q&A #3 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #3 file.

***********************************************************************************************************

Update 29 Dec 2020:

The purpose of this update is to provide Q&A #2 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #2 file.

***********************************************************************************************************

Update 22 Dec 2020:

The purpose of this update is to provide Q&A #1 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #1 file.

************************************************************************************************************

Description

Pursuant to Federal Acquisition Regulation (FAR) 15.201(e), this notice is issued as a Request for Information (RFI).  The Naval Air Systems Command is conducting market research to explore industry solutions related to FDA/EUA approved COVID 19 Testing options available in the commercial marketplace.  NAVAIR’s goal is to rapidly identify asymptomatic COVID-19 positive personnel in our on-station workforce as quickly as possible following an administered test.

Background

In response to the COVID pandemic, NAVAIR is seeking industry partners with a capability and capacity to immediately conduct regular, recurring and targeted COVID screening testing.  The below links within Supporting Information helped to inform NAVAIR’s requirement.  Please ensure your responses consider the information outlined in the CDC and NIH documents linked below.

Relevant Information

• Mass screening - This requirement may be fulfilled by either PCR molecular testing or antigen testing.  However, NAVAIR has a preference for PCR molecular testing with results reported within 24-48 hours.  Please describe your company’s ability to meet this requirement.  If your company does not provide PCR level testing, please explain an antigen based or other solution and address any specialized medical support that may be needed to administer such test.
• Targeted Screening – NAVAIR has a need to test small, high risk populations on an ad-hoc and/or daily basis.  These results are desired within one hour or less.  Please include in your response your capability to meet this requirement, how the test will be administered, how the individual results will be provided and address any specialized medical support that may be needed to administer such test 
• Reference Supporting Information #5, please include a response to your ability to meet the minimum, average and maximum proposed quantities by NAVAIR location.
• For mass screening and targeted screening, please ensure your response includes the COVID test name; FDA status (EUA, Off-Label usage, etc.); Lab CLIA Certificate Number; number of geographic sites that can be supported; number of tests per week/day that can be supported; how the test will be administered; turn-around time in hours for results; identification of any resources to be provided by the Government to assist in test administration; any new technologies you are pursuing to include status of FDA/EUA approval; and describe method for reporting to all applicable organizations (i.e. state health departments, individuals, NAVAIR, etc.)   
• Please describe any constraints regarding capacity, other customer needs, etc.
• Please provide a list of existing Federal and State Government contracts
• Please provide Rough Order of Magnitude (ROM) pricing for the requirements outlined herein

Supporting Information

The following links were used to inform this Sources Sought

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325181/ - The importance of test sensitivity versus frequency and turnaround time.
2. https://www.cdc.gov/coronavirus/2019-ncov/php/open-america/expanded-screening-testing.html - CDC report on use of asymptomatic COVID screening to reduce transmission
3. https://www.cdc.gov/mmwr/volumes/69/wr/mm6949e2.htm - CDC guidance on the importance of increased testing to identify asymptomatic individuals
4. ACRONYMS
   1. EUA – Emergency Use Authorization
   2. CLIA – Clinical Laboratory Improvement Amendments
   3. FDA- Food and Drug Administration
5. NAVAIR site location requirements:

Naval Base

Location

Geographic Zone

Targeted Weekly Screening Requirement

Minimum Weekly  Screening Requirement (10% of onsite population)

Average Weekly  Screening   Requirement (50% of onsite population)

Maximum Weekly Screening Requirements

Joint Base Lakehurst

Lakehurst, NJ

1

100

40

200

400

NAS Patuxent River

Patuxent River, MD

1

600

616

3,087

6,174

Webster Outlying Field

St. Inigoes, MD

1

75

70

350

700

NAS Oceana

Virginia Beach, VA

2

48

261

1,306

2,612

MCAS Cherry Point

Cherry Point, NC

2

344

344

1,721

3,442

NAS Jacksonville

Jacksonville, FL

2

274

473

2,365

4,730

NSA Orlando

Orlando, FL

2

43

40

200

400

NAS Whidbey Island

Whidbey Island, WA

3

15

97

483

966

NAS Lemoore

Lemoore, CA

3

18

123

613

1,226

NAWS China Lake

China Lake, CA

3

140

469

2,345

4,690

NAS Point Mugu

Point Mugu, CA

3

200

192

959

1,918

NAS North Island

San Diego, CA

3

304

473

2,366

4,732

TOTALS

 2,161

3,198

15,990

31,990

Due Date

• Please respond no later than 06 January 2021.  All questions must be sent to [email protected] and [email protected] with "COVID-19 Screening" in the subject line.

DISCLAIMER: 

• This announcement is for informational purposes only and does not commit the Government to award a contract as a result of this announcement.  This does not constitute a RFP or a promise to issue a RFP in the future. Further, the Government is not seeking proposals at this time and will not accept unsolicited proposals.
• The information provided herein is for informational purposes only. These requirements are subject to change based on the Government’s need. The final requirement, if any, will be defined under a formal RFP/RFQ. Not responding to this announcement does not preclude participation in any future RFP/RFQ, if issued. If a RFP/RFQ is released, it will be posted on the https://sam.gov website. Any subsequent amendments will also be posted to the https://sam.gov website. It is the responsibility of the potential offerors to monitor this website for additional information pertaining to this requirement.
• Respondents are advised that the Government will not pay for any information or administrative costs incurred in response to this announcement. All costs associated with responding to this announcement will be solely at the expense of the interested party.